Document:

EX-10.1

 Exhibit 10.1 

March 31, 2021 
 PERSONAL AND CONFIDENTIAL 

Edward Wholihan 
  

	Re:	 Transition Agreement 

Dear Ed: 
 This letter confirms your separation from full time
employment and continuation as a part-time consultant with Allena Pharmaceuticals, Inc. (the “Company”). We appreciate your contributions and would like to make this transition as smooth as possible for you. With that in mind, the
Company is offering you a transition and separation package as set forth in this transition agreement (the “Agreement”). 
  

	1.	 Transition Period 

Provided you enter into and comply with this Agreement, the Company will (i) continue to employ you as a full-time employee until March 31, 2021 and
(ii) engage you as a part-time, 1099 advisory consultant for the period of April 1, 2021 to December 31, 2021. You and the Company acknowledge and agree that the termination of your full-time employment is entirely voluntary and without Good
Reason (as defined in your Employment Agreement) and therefore you are not and will not be entitled to or eligible for any severance benefits under your Employment Agreement. 

The “Separation Date” shall be December 31, 2021 or any earlier date, if (in the case of such earlier date) your employment or service
relationship terminates due to you : (a) materially violating this Agreement; (b) resigning from the Company; or (c) engaging in behavior that justifies a termination for “Cause.” For purposes of this Agreement, Cause is
defined as any (i) felony, (ii)fraud, (iii) willful misconduct by you (iv) your refusal or failure to perform services for the Company under this Agreement after (in the case of (iv) only) written notice from the Company and 30
days to cure such refusal or failure. The time period between April 1, 2021 and the Separation Date shall be referred to herein as the “Transition Period.” The Company and you may mutually agree to extend the consulting portion
of the Transition Period, and thus the Separation Date. During the Transition Period, the Company will continue to indemnify you and defend you under its Director and Officers Insurance policy (the “D & O Policy”) to the fullest
extent permitted by and provided in such Policy. For clarification purposes, while you are employed by the Company as a full-time employee (i.e. until March 31, 2021), you will continue to receive your current base salary and you will be
eligible for regular employee benefits, subject to the terms of the Company’s benefit plans, except you will not be eligible for any bonus or incentive compensation. After the last day of your employment with the Company, the Company will pay
you for any accrued but unused vacation (subject to the Company’s vacation policy) and base salary through March 31, 2021 and you will be eligible to continue your group health benefits, subject to your eligibility under, and the terms of,
the COBRA law. 

 During the Transition Period , you will be available to the Company on a reasonable and mutually agreed on
(such agreement not to be unreasonably withheld by either you or the Company) basis to provide the Company with several areas of institutional knowledge and ongoing support. Specifically, you will provide institutional knowledge and support to the
Finance team regarding the Audit Committee, the Company’s budget, and previous investor discussions; and to the CMC team on vendor contracting. Additionally, you will participate in facilities planning and lease negotiations. However, as a
Consultant you will not make any decisions to bind the Company as your role is as an advisor only. The Company shall pay you $10,000 per month for nine (9) months for your consulting services, to be paid monthly in arrears. While you are
employed as a part-time consultant, you will not be eligible for any employee benefits, although you will be eligible for certain equity vesting and extended exercise periods as described in Section 2. 

You acknowledge and agree that (i) your obligations under the Restrictive Covenant Agreements, including with respect to nonsolicitation, noncompetition,
confidentiality and invention assignment, extend throughout the Transition Period; (ii) all references to “employment” in the Restrictive Covenant Agreements also include your service as a consultant under the Transition Period; and
(iii) the post-employment portions of your nonsolicitation and noncompetition period under the Restrictive Covenant Agreements do not begin to run until the Separation Date. 

For purposes of clarity, you may also work for another company during your Transition Period as long as you comply with all of your obligations to the
Company, including without limitation the Restrictive Covenant Obligations. 
  

	2.	 Additional Consideration 

In exchange for your promises herein, during the Transition Period through the Separation Date, you will continue to vest your Unvested Options with the
Company in accordance with the applicable stock option agreements and the Company’s equity plan (the “Equity Documents”). 
 To make sure you
and the Company have the same understanding, all of your Company stock options granted on September 15, 2016 and having a $1.59 strike price (167,031 options) are fully vested. 47,812 of your Company stock options granted on December 2, 2019
and having a $2.42 strike price are fully vested (along with the vested options described in the prior sentence, the “Vested Options”), and the remainder of such stock options granted on December 2, 2019 and having a $2.42
strike price are unvested (the “Unvested Options”). Subject to your compliance with this Agreement, the exercise period for the Vested Options (including any options that vest during the Transition Period) shall be extended until 90
days following the Separation Date (i.e. March 31, 2022, if the Separation Date occurs on December 31, 2021). You acknowledge that as a result of this extension of the exercise period, to the extent your Vested Options (including any options that
vest during the Transition Period) were incentive stock options, your Vested Options will convert from incentive stock options to nonqualified stock options, consistent with the Equity Documents and applicable law. You are advised to seek tax
guidance from your personal tax advisors with regard to the potential change in tax treatment of the Vested Options if you agree to the extension of the exercise period. Such stock options shall otherwise be subject to the Equity Documents. 

  
 2 

 Also, to be clear, while you have received other stock options granted on February 9, 2018 and March 4,
2019 (having a strike price of $6.91 and $6.70, respectively), those stock options shall lapse and be forfeited effective on the Effective Date (as defined below) and all underlying shares will be returned to the Company’s option pool for
future grants. Finally, you own 25,000 shares of common stock obtained on May 17, 2018 through the exercise of vested stock options. You also own 96,272 shares of common stock received on December 21, 2020 through the vesting and release
of RSUs granted by the Company. Except as described in this Section 2, you have no equity, RSU or other interest in the Company or any Company affiliate. 
  

	3.	 Release of Claims 

In consideration for, among other terms, the opportunity to continue your employment during the Transition Period and the Additional Consideration described in
Sections 1 and 2, to each of which you acknowledge you would otherwise not be entitled, you voluntarily release and forever discharge the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns,
its and their respective employee benefit plans and fiduciaries of such plans, and the current and former officers, directors, shareholders, employees, attorneys, accountants and agents of each of the foregoing in their official and personal
capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when you sign
this Agreement, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees, unless excluded below. This release includes, without limitation, all Claims: 

 

	•	 	 relating to your employment by and termination of employment with the Company; 

 

	•	 	 of wrongful discharge or violation of public policy; 

 

	•	 	 of breach of contract; 

 

	•	 	 of defamation or other torts; 

 

	•	 	 of retaliation or discrimination under federal, state or local law (including, without limitation, Claims of
discrimination, retaliation or otherwise under the Americans with Disabilities Act, Age Discrimination in Employment Act, and Title VII of the Civil Rights Act of 1964); 

 

	•	 	 under any other federal or state statute; 

 

	•	 	 for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation or
benefits, including without limitation, pursuant to the Massachusetts Wage Act; and 

  

	•	 	 for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages,
injunctive relief and attorney’s fees; 

 provided, however, that this release shall not affect your rights under this
Agreement. Further, you are not releasing your rights or claims to: indemnification and defense for your former role as Chief Financial Officer of the Company or your role as an advisory consultant during the Transition Period, in each case to the
extent provided in the D & O Policy; and/or your vested equity. 
 You agree not to accept damages of any nature, other equitable or legal remedies
for your own benefit or attorney’s fees or costs from any of the Releasees with respect to any Claim released by this Agreement. As a material inducement to the Company to enter into this Agreement, you represent that you have not assigned any
Claim to any third party. 

  
 3 

 You acknowledge and represent that, except as expressly provided in this Agreement, the Company has paid or
provided all salary, wages, bonuses, accrued vacation/paid time off, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses, commissions, stock, stock options, vesting, and any
and all other benefits and compensation due to you. 
  

	4.	 Confidential Information 

You understand and agree that you have been employed in a position of confidence and trust and have had access to information concerning the Company that the
Company treats as confidential and the disclosure of which could negatively affect the Company’s interests (“Confidential Information”). Confidential Information includes, without limitation, confidential financial
information; business forecasts; inventions; improvements and other intellectual property; trade secrets; know-how; designs, processes or formulae; confidential software; marketing or sales information or
plans; customer lists; and business plans, prospects and opportunities. You agree that you shall not use or disclose any Confidential Information at any time without the written consent of the Company. 

 

	5.	 Continuing Obligations 

You are subject to continuing obligations under your Invention and Nondisclosure Agreement, dated June 9, 2016, and your
Non-Competition and Non-Solicitation Agreement, dated June 9, 2016 and amended on October 17, 2017 (the “Noncompete Agreement,” and together,
the “Restrictive Covenant Agreements”). Section 1(a) of the Noncompete Agreement is hereby amended by replacing “the development and commercialization of therapeutics to treat rare and severe metabolic and kidney
disorders” with “the development and commercialization of therapeutics for the treatment of hyperoxaluria or hyperuricemia.” The Noncompete Agreement, as amended herein, remains in full effect, and you agree that you are not eligible
for or entitled to any garden leave pay or additional consideration in connection with the Noncompete Agreement. The Restrictive Covenant Agreements are referred to as the “Continuing Obligations,” remain in full effect and are
incorporated by reference herein. 
  

	6.	 Confidentiality of Agreement-Related Information 

You agree, to the fullest extent permitted by law, to keep all Agreement-Related Information completely confidential. “Agreement-Related
Information” means the negotiations leading to this Agreement and the existence and terms of this Agreement. Notwithstanding the foregoing, you may disclose Agreement-Related Information to your spouse, your attorney and your financial
advisors, and to them only provided that they first agree for the benefit of the Company to keep Agreement-Related Information confidential. You represent that during the period since the date of this letter, you have not made any disclosures that
would have been contrary to the foregoing obligation if it had then been in effect. Nothing in this section shall be construed to prevent you from disclosing Agreement-Related Information to the extent required by a lawfully issued subpoena or duly
issued court order; provided that you provide the Company with advance written notice and a reasonable opportunity to contest such subpoena or court order. 

  
 4 

	7.	 Non-Disparagement 

You agree not to make any disparaging statements concerning the Company or any of its affiliates, products, services or current or former officers, directors,
shareholders, employees or agents. You represent that during the period since the date of this letter, you have not made any such disparaging statements. 
  

	8.	 Return of Property 

You confirm that, to the best of your knowledge, you will return to the Company by the Separation Date all Company property, including, without limitation,
computer equipment, software, keys and access cards, credit cards, files and any documents (including computerized data and any copies made of any computerized data or software) containing information concerning the Company, its business or its
business relationships. You also commit to deleting and finally purging any duplicates of files or documents that may contain Company information from any computer or other device that remains your property after the Separation Date. In the event
that you discover that you continue to retain any such property, you shall return it to the Company immediately. 
  

	9.	 Protected Disclosures and Other Protected Actions 

Nothing contained in this Agreement limits your ability to file a charge or complaint with any federal, state or local governmental agency or commission (a
“Government Agency”). In addition, nothing contained in this Agreement limits your ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government
Agency, including your ability to provide documents or other information, without notice to the Company, nor does anything contained in this Agreement apply to truthful testimony in litigation. If you file any charge or complaint with any Government
Agency and if the Government Agency pursues any claim on your behalf, or if any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized relief (either individually or as part of any collective or
class action). 
 In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or
civilly liable under any federal or state trade secret law or under this Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or
to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

 

	10.	 Other Provisions 

(a) Termination and Return of Payments; Certain Remedies. If a court of competent jurisdiction determines that you have materially breached any of your
obligations under this Agreement, including without limitation any of your material obligations in your Restrictive Covenant Agreements, in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the
right to terminate and/or enforce the return of its non-wage payments to you or for your benefit under this Agreement. The termination and/or return of such payments in the event of your material breach will
not affect your continuing obligations under this Agreement. Without limiting the Company’s remedies hereunder, if the Company prevails in any action to enforce this Agreement, then you shall be liable to the Company for reasonable
attorneys’ fees and costs incurred by the Company in connection with such action. 

  
 5 

 (b) Absence of Reliance. In signing this Agreement, you are not relying
upon any promises or representations made by anyone at or on behalf of the Company. 
 (c) Enforceability. If any portion or provision of this
Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the
application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law. 
 (d) Waiver. No waiver of any provision of this Agreement shall be effective unless made in writing and signed by
the waiving party. The failure of a party to require the performance of any term or obligation of this Agreement, or the waiver by a party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach. 
 (e) Jurisdiction. You and the Company hereby agree that the state and federal courts of Massachusetts
shall have the exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim of a violation of this Agreement. With respect to any such court action, you submit to the jurisdiction of such courts
and you acknowledge that venue in such courts is proper. 
 (f) Governing Law; Interpretation. This Agreement shall be interpreted and enforced under
the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles. In the event of any dispute, this Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning,
and not to be construed strictly for or against either you or the Company or the “drafter” of all or any portion of this Agreement. 
 (g)
Entire Agreement. This Agreement, the Continuing Obligations and the Equity Documents constitute the entire agreement between you and the Company and supersede any previous agreements or understandings between you and the Company, including
without limitation the Employment Agreement. This Agreement is binding on the Company’s successors and assigns. You may not assign this Agreement. 

(h) Time for Consideration; Effective Date. 

The Company previously proposed an agreement to you in an Agreement provided to you on March 24, 2021 (the “Initial Proposal”). You were
given the opportunity to consider the Initial Proposal for twenty-one (21) days from the date of the Initial Proposal (the “Consideration Period”). The Company proposed this
Agreement in place of the Initial Proposal following discussions between the parties. The last day of the Consideration Period remains unchanged by the offer of this Agreement in place of the Initial Proposal.. You acknowledge that the above 

  
 6 

 release of claims expressly includes without limitation claims under the Age Discrimination in Employment
Act. You are advised to consult with an attorney before signing this Agreement. To accept this Agreement, you must return a signed original or a signed PDF copy of this Agreement so that it is received by the undersigned at or before the expiration
of the Consideration Period. If you sign this Agreement before the end of the Consideration Period, you acknowledge by signing this Agreement that such decision was entirely voluntary and that you had the opportunity to consider this Agreement for
the entire Consideration Period. For the period of seven (7) business days from the date when you sign this Agreement, you have the right to revoke this Agreement by written notice to the undersigned. For such a revocation to be effective, it
must be delivered so that it is received by the undersigned at or before the expiration of the seven (7) business day revocation period (the “Revocation Period”). This Agreement shall not become effective or enforceable during
the Revocation Period. It will become effective on the day after the Revocation Period ends (the “Effective Date.”) 
 (i)
Counterparts. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. 

Please indicate your agreement to the terms of this Agreement by signing and returning to the undersigned the original or a PDF copy of this letter within the
time period set forth above. 
 Sincerely, 
 ALLENA
PHARMACEUTICALS, INC. 
  

							
	By:	  	 /s/ Louis Brenner
	  	        	  	 March 31, 2021

		  	 Louis Brenner
 President and Chief Executive
Officer
	  		  	Date

 This is a legal document. Your signature will commit you to its terms. By signing below, you acknowledge that you have
carefully read and fully understand all of the provisions of this Agreement and that you are knowingly and voluntarily entering into this Agreement. 
  

							
	By:	  	 /s/ Edward Wholihan
	  	        	  	 March 31, 2021

		  	Edward Wholihan	  		  	Date

  
 7rcrt_ex10-1

  Exhibit
10.1

 

DIRECTOR
AGREEMENT

 

This
DIRECTOR AGREEMENT is made as of February 12, 2021 (the
“Agreement”), by and
between Recruiter.com Group, Inc., a Nevada corporation (the
“Company”), and Steve
Pemberton, an individual with an address of 861 Hunter Lane Lake
Forest, Illinois 60045 (the “Director”).

 

WHEREAS, the Board
of Directors of the Company (the “Board”) approved Director
on to serve as a member of the Board, and desires to enter into an
agreement with the Director with respect to such appointment;
and

 

WHEREAS, the
Director is willing to accept such appointment and to serve the
Company on the terms set forth herein and in accordance with the
provisions of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants contained
herein, the parties hereto agree as follows:

 

1. Position. Subject to the terms
and provisions of this Agreement, the Company shall cause the
Director to be appointed, and the Director hereby agrees to serve
the Company in such position, upon the terms and conditions
hereinafter set forth, provided, however, that the
Director’s continued service on the Board of Directors of the
Company (the “Board”) after the next
annual stockholders’ meeting shall be subject to approval by
the Company’s stockholders.

 

2.    
Duties.

 

(a) During the
Directorship Term (as defined herein), the Director shall make
reasonable business efforts to attend all Board meetings, serve on
appropriate subcommittees as reasonably requested by the Board,
make himself available to the Company at mutually convenient times
and places, attend external meetings and presentations, as
appropriate and convenient, and perform such duties, services and
responsibilities, and have the authority commensurate to such
position.

 

(b) The Director will
use his best business efforts to promote the interests of the
Company. The Company recognizes that the Director (i) is or may
become a full-time executive employee of another entity and that
his responsibilities to such entity must have priority and (ii)
sits or may sit on the board of directors of other entities.
Notwithstanding the same, the Director will use reasonable business
efforts to coordinate his respective commitments so as to fulfill
his obligations to the Company and, in any event, will fulfill his
legal obligations as a Director. Other than as set forth above, the
Director will not, without the prior notification to the Board,
engage in any other business activity which could materially
interfere with the performance of his duties, services and
responsibilities hereunder or which is in violation of the
reasonable policies established from time to time by the Company,
provided that the
foregoing shall in no way limit his activities on behalf of (i) any
current employer and its affiliates or (ii) the board of directors
of any entities on which he currently sits. At such time as the
Board receives such notification, the Board may require the
resignation of the Director if it determines that such business
activity does

 

 

 

 

in fact
materially interfere with the performance of the Director’s
duties, services and responsibilities hereunder.

 

3.   
Compensation.

 
(a) Cash Stipend. The
Director shall receive an annual cash stipend of Twenty Thousand
Dollars ($20,000).

 

(b) Stock Options. The
Director shall receive, upon execution of this Agreement, a
non-qualified stock option to purchase up to fifty thousand
(50,000) shares of the Company’s common stock at an exercise
price per share equal to $3.25. Such option shall be exercisable
for a period of 3 years. The option shall vest in equal amounts
over a period of three years, and such vesting schedule shall be no
less favorable than the vesting schedule applicable to other
directors of the Company. Notwithstanding the foregoing, if the
Director ceases to be a member of Board at any time during the
three-year vesting period for any reason (such as resignation,
withdrawal, death, disability or any other reason), then any
un-vested options shall be forfeited. Upon the occurrence of a
Change in Control, any un-vested options shall vest immediately,
provided the Director serves on the Board as of the date of such
Change in Control. “Change in Control” shall
mean any sale, conveyance, assignment or other transfer, directly
or indirectly, of any ownership interest of the Company, which
results in any change in the identity of the individuals or
entities in Control of the Company. “Control” shall mean the
possession, directly or indirectly, of the material assets of the
Company or of of the power to direct, or cause the direction of,
the management and policies of a person by contract, voting of
securities, or otherwise.

 

(c) Independent
Contractor. The Director’s status during the Directorship
Term shall be that of an independent contractor and not, for any
purpose, that of an employee or agent with authority to bind the
Company in any respect. All payments and other consideration made
or provided to the Director under this Section 3 shall be made or
provided without withholding or deduction of any kind, and the
Director shall assume sole responsibility for discharging all tax
or other obligations associated therewith.

 

(d) Expense
Reimbursements. During the Directorship Term, the Company shall
reimburse the Director for (i) all reasonable out-of-pocket
expenses incurred by the Director in attending any in-person
meetings, provided
that the Director complies with the generally applicable policies,
practices and procedures of the Company for submission of expense
reports, receipts or similar documentation of such expenses, and
(ii) any costs associated with filings required to be made by the
Director or any of the entities managed or controlled by Director
to report beneficial ownership or the acquisition or disposition of
securities of the Company. Any reimbursements for allocated
expenses (as compared to out-of-pocket expenses of the Director)
must be approved in advance by the Company.

 

4. Directorship Term. The
“Directorship
Term,” as used in this Agreement, shall mean the
period commencing on the date hereof and terminating on the earlier
of the date of the next annual stockholders meeting and the
earliest of the following to occur:

 

 

2

 

 

(a)    
the death of the Director;

 

(b) the termination of
the Director from his membership on the Board by the mutual
agreement of the Company and the Director;

 

(c) the removal of the
Director from the Board by the majority stockholders of the
Company; and

 

(d) the resignation
by the Director from the Board.

 

5. Director’s Representation and
Acknowledgment. The Director represents to the Company that
his execution and performance of this Agreement shall not be in
violation of any agreement or obligation (whether or not written)
that he may have with or to any person or entity, including without
limitation, any prior or current employer. The Director hereby
acknowledges and agrees that this Agreement (and any other
agreement or obligation referred to herein) shall be an obligation
solely of the Company, and the Director shall have no recourse
whatsoever against any officer, director, employee, stockholder,
representative or agent of the Company or any of their respective
affiliates with regard to this Agreement.

 

6.    
Director
Covenants.

 

(a) Unauthorized
Disclosure. The Director agrees and understands that in the
Director’s position with the Company, the Director has been
and will be exposed to and receive information relating to the
confidential affairs of the Company, including, but not limited to,
technical information, business and marketing plans, strategies,
customer information, other information concerning the
Company’s products, services, promotions, development,
financing, expansion plans, business policies and practices, and
other forms of information considered by the Company to be
confidential, and proprietary and in the nature of trade secrets.
The Director agrees that during the Directorship Term and
thereafter, the Director will keep such information confidential
and will not disclose such information, either directly or
indirectly, to any third person or entity without the prior written
consent of the Company; provided, however, that (i) the Director
shall have no such obligation to the extent such information (A) is
or becomes publicly known or generally known in the Company’s
industry other than as a result of the Director’s breach of
his obligations hereunder; (B) was properly known to the Director,
without restriction, prior to disclosure by Company; or (C) is
obtained from a third party without an accompanying duty of
confidentiality and without a breach of such third party’s
obligations of confidentiality; and (ii) the Director may, after
giving prior notice to the Company to the extent practicable under
the circumstances, disclose such information to the extent required
by applicable laws or governmental regulations or judicial or
regulatory process. This confidentiality covenant has no temporal,
geographical or territorial restriction. Upon termination of the
Directorship Term, the Director will promptly return to the Company
and/or destroy at the Company’s direction all property, keys,
notes, memoranda, writings, lists, files, reports, customer lists,
correspondence, tapes, disks, cards, surveys, maps, logs, machines,
technical data, other product or document, and any summary or
compilation of the foregoing, in whatever form, including, without
limitation, in electronic form, which has been produced by,
received by or otherwise submitted to the Director in the course or
otherwise as a result of the Director’s position with the
Company during or prior to the Directorship

 

 

3

 

 

Term
(except that the Director may keep personal copies of (i) his
compensation records, (ii) materials distributed to shareholders
generally and (iii) any written agreement to which he is a party),
provided that the
Company shall retain such materials and make them available to the
Director if requested by him in connection with any litigation
against the Director under circumstances in which (i) the Director
demonstrates to the reasonable satisfaction of the Company that the
materials are necessary to his defense in the litigation and (ii)
the confidentiality of the materials is preserved to the reasonable
satisfaction of the Company.

 

(b)   
Non-Solicitation. During the Directorship Term and for a period of
three (3) years
thereafter, the Director shall not interfere with the
Company’s relationship with, or endeavor to entice away from
the Company, any person who, on the date of the termination of the
Directorship Term and/or at any time during the one year period
prior to the termination of the Directorship Term, was an employee
or customer (including those reasonably expected to be a customer)
of the Company or otherwise had a material business relationship
with the Company.

 

(c) Remedies. The
Director agrees that any breach of the terms of this Section 6
could result in irreparable injury and damage to the Company for
which the Company would have no adequate remedy at law. The
Director therefore also agrees that in the event of said breach or
any threat of breach, the Company shall be entitled to an immediate
injunction and restraining order to prevent such breach and/or
threatened breach and/or continued breach by the Director and/or
any and all entities acting for and/or with the Director, without
having to prove damages or paying a bond, in addition to any other
remedies to which the Company may be entitled at law or in equity.
The terms of this paragraph shall not prevent the Company from
pursuing any other available remedies for any breach or threatened
breach hereof, including, but not limited to, the recovery of
damages from the Director. The Director acknowledges that the
Company would not have entered into this Agreement had the Director
not agreed to the provisions of this Section 6.

 

(d) The provisions of
this Section 6 shall survive any termination of the Directorship
Term, and the existence of any claim or cause of action by the
Director against the Company, whether predicated on this Agreement
or otherwise, shall not constitute a defense to the enforcement by
the Company of the covenants and agreements of this Section
6.

 

7. Indemnification. The Company
agrees to indemnify the Director for his activities as a member of
the Board as set forth in the Director and Officer Indemnification
Agreement attached hereto as Exhibit
A.

 

8. Non-Waiver of Rights. The
failure to enforce at any time the provisions of this Agreement or
to require at any time performance by the other party hereto of any
of the provisions hereof shall in no way be construed to be a
waiver of such provisions or to affect either the validity of this
Agreement or any part hereof, or the right of either party hereto
to enforce each and every provision in accordance with its terms.
No waiver by either party hereto of any breach by the other party
hereto of any provision of this Agreement to be performed by such
other party shall be deemed a waiver of similar or dissimilar
provisions at that time or at any prior or subsequent
time.

 

 

4

 

 

9. Notices. Every notice relating
to this Agreement shall be in writing and shall be given by
personal delivery, overnight delivery or by registered or certified
mail, postage prepaid, return receipt requested; to:

 

If to
the Company:

 

Recruiter.com
Group, Inc.

100
Waugh Dr. Suite 300

Houston, Texas
77007

Attn:
Evan Sohn, Chief Executive Officer

Telephone: (855)
931-1500

Email:
evan@recruiter.com

 

with a
copy (which shall not constitute notice) to:

 

Lucosky
Brookman LLP

101
Wood Avenue South

Woodbridge, New
Jersey 08830

Attn:
Joseph M. Lucosky, Esq.

Telephone: (732)
395-4400

Email:
jlucosky@lucbro.com

If to
the Director:

 

Steve
Pemberton

861
Hunter Lane

Lake
Forest, IL, 60045

 

Either
of the parties hereto may change their address for purposes of
notice hereunder by giving notice in writing to such other party
pursuant to this Section 9.

 

10. Binding Effect/Assignment. This
Agreement shall inure to the benefit of and be binding upon the
parties hereto and their respective heirs, executors, personal
representatives, estates, successors (including, without
limitation, by way of merger) and assigns, as applicable.
Notwithstanding the provisions of the immediately preceding
sentence, neither the Director nor the Company shall assign all or
any portion of this Agreement without the prior written consent of
the other party.

 

11. Entire Agreement. This
Agreement (together with the other agreements referred to herein)
sets forth the entire understanding of the parties hereto with
respect to the subject matter hereof and supersedes all prior
agreements, written or oral, between them as to such subject
matter.

 

12. Severability. If any provision
of this Agreement, or any application thereof to any circumstances,
is invalid, in whole or in part, such provision or application
shall to that extent be severable and shall not affect other
provisions or applications of this Agreement.

 

 

5

 

 

13. Governing Law. This Agreement
and the legal relations among the parties shall be governed by, and
construed and enforced in accordance with, the laws of the State of
Nevada, without regard to its conflict of laws rules. The parties
hereto hereby irrevocably and unconditionally (i) agree that any
action or proceeding arising out of or in connection with this
Agreement shall be brought in any court of the State of Nevada (the
“Nevada
Court”), and not in any other state or federal court
in the United States of America or any court in any other country,
(ii) consent to submit to the exclusive jurisdiction of the Nevada
Court for purposes of any action or proceeding arising out of or in
connection with this Agreement, (iii) waive any objection to the
laying of venue of any such action or proceeding in the Nevada
Court, and (v) waive, and agree not to plead or to make, any claim
that any such action or proceeding brought in the Nevada Court has
been brought in an improper or inconvenient forum.

 

14. Legal Fees. The parties hereto
agree that the non-prevailing party in any dispute, claim, action
or proceeding between the parties hereto arising out of or relating
to the terms and conditions of this Agreement or any provision
thereof (a “Dispute”), shall
reimburse the prevailing party for reasonable attorney’s fees
and expenses incurred by the prevailing party in connection with
such Dispute; provided, however, that the Director
shall only be required to reimburse the Company for its fees and
expenses incurred in connection with a Dispute if the
Director’s position in such Dispute was found by the court,
arbitrator or other person or entity presiding over such Dispute to
be frivolous or advanced not in good faith.

 

15. Modifications. Neither this
Agreement nor any provision hereof may be modified, altered,
amended or waived except by an instrument in writing duly signed by
both parties, which writing explicitly states the intent of both
parties hereto to supplement the terms herein.

 

16. Tense and Headings. Whenever
any words used herein are in the singular form, they shall be
construed as though they were also used in the plural form in all
cases where they would so apply. The headings contained herein are
solely for the purposes of reference, are not part of this
Agreement and shall not in any way affect the meaning or
interpretation of this Agreement.

 

17. Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be
deemed to be an original but all of which together shall constitute
one and the same instrument.

 

[-Signature Page Follows-]

 

 

6

 

 

IN
WITNESS WHEREOF, the Company has caused this Director Agreement to
be executed by authority of its Board of Directors, and the
Director has hereunto set his hand, on the day and year first above
written.

 

 

 

RECRUITER.
COM GROUP, INC.

 

 

 

By:

Evan
Sohn

Chief
Executive Officer

 

 

 

 

DIRECTOR

 

Steve
Pemberton, an individual

 

 

	

[Signature page to
Director Agreement]

 

 

 

EXHIBIT A

 

DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT

 

 

See
attached.

 

 

 

 

 

 

 

 

 

 

	

[Exhibit A to
Director Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]